| Attending joint formulation meetings on pharmaceuticals and special medical materials. | Kanker
> Kanker: de meeste soorten | Regelgevend partnerschap
> Werken met regelgevende instanties | 100.000 | National | Sometimes | 119017792133 |
| At year-end, regulatory authorities, cancer patient advocacy groups, and clinical physicians are invited to review the NHI [全民健康保險 – National Health Insurance] reimbursement policies for that year. | Kanker
> Kanker: de meeste soorten | Regelgevend partnerschap
> Werken met regelgevende instanties | 5.000 | National | Sometimes | 119022421395 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Kanker
> Kanker: de meeste soorten | Regelgevend partnerschap
> Deelnemen aan Health Technology Assessment (HTA) en vergoedingsbeoordelingen | 5.000 | National | Sometimes | 119022421395 |
| We communicate patient needs to the National Health Insurance Administration in order to improve patient access to treatment. | Neuromusculair
> Spinale musculaire atrofie (SMA) | Regelgevend partnerschap
> Deelnemen aan Health Technology Assessment (HTA) en vergoedingsbeoordelingen | 100 | National | Regularly | 119053648739 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Kanker
> Kanker: de meeste soorten | Regelgevend partnerschap
> Bijwonen/faciliteren van vergaderingen met beleidsmakers/regelgevers | 5.000 | National | Sometimes | 119022421395 |
| At year-end, regulatory authorities, cancer patient advocacy groups, and clinical physicians are invited to review the NHI [全民健康保險 – National Health Insurance/Taiwan] reimbursement policies for that year. | Kanker
> Kanker: de meeste soorten | Regelgevend partnerschap
> Bijwonen/faciliteren van vergaderingen met beleidsmakers/regelgevers | 5.000 | National | Sometimes | 119022421395 |
| ... Since 2025, the government [in Taiwan] has also begun implementing its Cancer New Drug Fund policy, and our organisation is recognised as one of 13 patient advocacy groups whose efforts contributed to that successful outcome. | Kanker
> Kanker: de meeste soorten | Beleid en wetgeving beïnvloeden
> Beïnvloed het gezondheidsbeleid en de wetgeving | 10.000 | National | Sometimes | 119055308347 |
| With regard to pricing, we have not had the opportunity to participate in discussions, as prices are largely determined by pharmaceutical companies' global headquarters, with patient advocacy groups afforded no meaningful role in the process. Nevertheless, we actively present patients' clinical medication needs to the government in cases where reimbursement under Taiwan's NHI [全民健康保險 – National Health Insurance] is unavailable, with the aim of securing alternative funding mechanisms to support cancer patients — such as a dedicated cancer medicines fund. | Kanker
> Kanker: de meeste soorten | Beleid en wetgeving beïnvloeden
> Deelnemen aan openbare hoorzittingen en raadplegingen | 10.000 | National | Sometimes | 119055325391 |
| To advocate for the expansion of reimbursement coverage for new medicines to encompass broader therapeutic indications. | Algemene gezondheid
> Gezondheidszorgverlening | Pleitbezorging voor prijsstelling en betaalbaarheid
> Pleit voor eerlijke medicijnprijzen | 5.000 | National | Sometimes | 119051396882 |
| We are advocating for the inclusion of immunotherapy for early-stage triple-negative breast cancer patients within the reimbursement coverage of the National Health Insurance scheme. | Kanker
> Kanker: borst | Pleitbezorging voor prijsstelling en betaalbaarheid
> Pleiten voor opname van het product in vergoedingslijsten/nationale formularia | 10.000 | National | Regularly | 119016883314 |
| To advocate for the expansion of reimbursement coverage for new medicines to encompass broader therapeutic indications. | Algemene gezondheid
> Gezondheidszorgverlening | Pleitbezorging voor prijsstelling en betaalbaarheid
> Pleiten voor opname van het product in vergoedingslijsten/nationale formularia | 5.000 | National | Sometimes | 119051396882 |
| Advocating for the expansion of reimbursement coverage for new medicines to encompass broader indications. | Kanker
> Kanker: neuro-endocrien (NET) | Pleitbezorging voor prijsstelling en betaalbaarheid
> Pleiten voor opname van het product in vergoedingslijsten/nationale formularia | 100 | National | Sometimes | 119051407743 |
| With regard to pricing, we have not had the opportunity to participate in discussions, as prices are largely determined by pharmaceutical companies' global headquarters, with patient advocacy groups afforded no meaningful role in the process. Nevertheless, we actively present patients' clinical medication needs to the government in cases where reimbursement under Taiwan's NHI [全民健康保險 – National Health Insurance] is unavailable, with the aim of securing alternative funding mechanisms to support cancer patients — such as a dedicated cancer medicines fund. | Kanker
> Kanker: de meeste soorten | Pleitbezorging voor prijsstelling en betaalbaarheid
> Pleiten voor opname van het product in vergoedingslijsten/nationale formularia | 10.000 | National | Sometimes | 119055325391 |
| We are advocating for the inclusion of immunotherapy for early-stage triple-negative breast cancer patients within the reimbursement coverage of the National Health Insurance scheme. | Kanker
> Kanker: borst | Toegangspaden verbeteren
> Faciliteer gelijke toegang tot medicijnen/gezondheidszorg | 10.000 | National | Regularly | 119016883314 |
| Advocating for the expansion of reimbursement coverage for new medicines to encompass broader indications. | Kanker
> Kanker: neuro-endocrien (NET) | Toegangspaden verbeteren
> Faciliteer gelijke toegang tot medicijnen/gezondheidszorg | 100 | National | Sometimes | 119051407743 |
| We communicate patient needs to the National Health Insurance Administration in order to improve patient access to treatment. | Neuromusculair
> Spinale musculaire atrofie (SMA) | Toegangspaden verbeteren
> Faciliteer gelijke toegang tot medicijnen/gezondheidszorg | 100 | National | Regularly | 119053648739 |
| In advocating for patient rights and access to new medicines, we engage with stakeholders, government authorities, and relevant experts to communicate patients' clinical needs and the urgency of treatment. | Kanker
> Kanker: de meeste soorten | Toegangspaden verbeteren
> Faciliteer gelijke toegang tot medicijnen/gezondheidszorg | 10.000 | National | Sometimes | 119055308347 |
| Convene an annual year-end review bringing together regulatory authorities, cancer patient advocacy organisations, and clinical physicians to evaluate the NHI reimbursement policies for that calendar year. Patient advocacy groups present on unmet patient needs, clinicians conduct a cancer-type-specific assessment of the gaps between Taiwan's NHI [全民健康保險 – National Health Insurance] reimbursement coverage and oncology treatment guidelines, and dialogue is facilitated with the regulatory authorities. | Kanker
> Kanker: de meeste soorten | Op bewijs gebaseerde patiëntinbreng
> Gebruik patiëntinzichten om beslissingen te onderbouwen | 5.000 | National | Sometimes | 119022421395 |
| We serve as members of the Infected Persons Rights Protection Committee under Taiwan CDC [Centers for Disease Control]. | HIV
> HIV | Institutioneel bestuur
> Zorg voor vertegenwoordiging binnen gouvernementele adviesorganen | 5.000 | National | Regularly | 119021698989 |
| In advocating for patient rights and access to new medicines, we engage with stakeholders, government authorities, and relevant experts to communicate patients' clinical needs and the urgency of treatment. | Kanker
> Kanker: de meeste soorten | Institutioneel bestuur
> Effectief werken binnen netwerken met meerdere belanghebbenden | 10.000 | National | Sometimes | 119055308347 |
interacties
acties & belangenbehartiging
5 vermeldingen
